The stock of Kintara Therapeutics Inc (NASDAQ: KTRA) has decreased by -2.21 when compared to last closing price of 0.21.Despite this, the company has seen a loss of -9.27% in its stock price over the last five trading days. prnewswire.com reported 2024-08-19 that 30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 TAMPA, Fla. & SAN DIEGO, August 19, 2024 /PRNewswire/ — TuHURA Biosciences, Inc. (“TuHURA”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Kineta, Inc. (Nasdaq: KA) (“Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, has reopened enrollment in its ongoing VISTA-101 Phase 1/2 clinical trial.
Is It Worth Investing in Kintara Therapeutics Inc (NASDAQ: KTRA) Right Now?
Company’s 36-month beta value is 0.81.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for KTRA is 55.36M, and currently, short sellers hold a 2.76% ratio of that floaft. The average trading volume of KTRA on August 27, 2024 was 9.33M shares.
KTRA’s Market Performance
The stock of Kintara Therapeutics Inc (KTRA) has seen a -9.27% decrease in the past week, with a -9.86% drop in the past month, and a 10.43% gain in the past quarter. The volatility ratio for the week is 10.11%, and the volatility levels for the past 30 days are at 11.16% for KTRA. The simple moving average for the last 20 days is 2.70% for KTRA’s stock, with a simple moving average of 10.25% for the last 200 days.
KTRA Trading at -12.48% from the 50-Day Moving Average
After a stumble in the market that brought KTRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -95.85% of loss for the given period.
Volatility was left at 11.16%, however, over the last 30 days, the volatility rate increased by 10.11%, as shares sank -7.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.53% upper at present.
During the last 5 trading sessions, KTRA fell by -9.01%, which changed the moving average for the period of 200-days by -50.10% in comparison to the 20-day moving average, which settled at $0.2013. In addition, Kintara Therapeutics Inc saw 22.35% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for KTRA
The total capital return value is set at -1.57. Equity return is now at value -192.23, with -131.55 for asset returns.
Currently, EBITDA for the company is -14.75 million with net debt to EBITDA at 0.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.04.
Conclusion
In a nutshell, Kintara Therapeutics Inc (KTRA) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
